Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Clinical Lung Cancer
Fred R HirschNick Thatcher

Abstract

Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.

Citations

Jan 11, 2020·Journal of Magnetic Resonance Imaging : JMRI·Jessica A MartinezDaniel B Ennis
Feb 14, 2019·Journal of Experimental & Clinical Cancer Research : CR·Peng LuoBaolong Wang
Jun 12, 2021·Frontiers in Oncology·Kenneth K W ToWilliam C S Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
J BennounaJ-Y Douillard
Journal of the National Cancer Institute
Paul A Bunn, Rogerio Lilenbaum
© 2022 Meta ULC. All rights reserved